WPD Pharmaceuticals’ License Partner, Moleculin Biotech to Host Conference Call to Discuss COVID-19 Potential in WP1122 Dru...
April 16 2020 - 3:05AM
WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1)
(the
“Company” or
“WPD”) a
clinical stage pharmaceutical company announces that its license
partner, Moleculin Biotech, Inc. (“
Moleculin”)
will be hosting a web-based investor conference call, today, April
16th at 4:30pm ET to explain the significance of the recent
discovery that the active compound in WP1122 drug candidate has
been shown to reduce replication of SARS-CoV-2 by 100%. WPD has
licensed rights to a portfolio of drug candidates, including WP1122
through Moleculin.
Details of the conference call are below:
Date: |
April 16,
2020 |
Time: |
4:30 – 5:00 PM ET |
Link: |
https://edge.media-server.com/mmc/p/xihchttv |
About WPD Pharmaceuticals
WPD is a biotechnology research and development
company with a focus on oncology, namely research and development
of medicinal products involving biological compounds and small
molecules. WPD has 10 novel drug candidates with 4 that are
in clinical development stage. These drug candidates were
researched at institutions including the Mayo Clinic and Emory
University, and WPD currently has ongoing collaborations with Wake
Forest University and leading hospitals and academic centers in
Poland.
WPD has entered into license agreements with
Wake Forest University Health Sciences and sublicense agreements
with Moleculin Biotech, Inc. and CNS Pharmaceuticals, Inc.,
respectively, each of which grant WPD an exclusive, royalty-bearing
sublicense to certain technologies of the licensor. Such agreements
provide WPD with certain research, development, manufacturing and
sales rights, among other things. The sublicense territory
from CNS Pharmaceuticals and Moleculin Biotech includes 31
countries in Europe and Asia, including Russia.
On Behalf of the Board
‘Mariusz Olejniczak’
Mariusz OlejniczakCEO, WDP Pharmaceuticals
Contact:
Investor RelationsEmail:
investors@wpdpharmaceuticals.com Tel: 604-428-7050Web:
www.wpdpharmaceuticals.com
Cautionary Statements:
Neither the Canadian Securities Exchange nor the
Investment Industry Regulatory Organization of Canada accepts
responsibility for the adequacy or accuracy of this release.
This press release contains forward-looking
statements. Forward-looking statements are statements that
contemplate activities, events or developments that the Company can
develop effective drugs against cancer and possibly SARS Covid
-19. Factors which may prevent the forward looking statement
from being realized include that competitors or others may
successfully challenge a granted patent and the patent could be
rendered void; that we are unable to raise sufficient funding for
our research; that we may not meet the requirements to receive the
grants awarded; that our drugs don’t provide positive treatment, or
if they do, the side effects are damaging; competitors may develop
better or cheaper drugs; and we may be unable to obtain regulatory
approval for any drugs we develop. Readers should refer to the risk
disclosure included from time-to-time in the documents the Company
files on SEDAR, available at www.sedar.com. Although the
Company believes that the assumptions inherent in these
forward-looking statements are reasonable, they are not guarantees
of future performance and, accordingly, they should not be relied
upon and there can be no assurance that any of them will prove to
be accurate. Finally, these forward-looking statements are
made as of the date of this press release and the Company assumes
no obligation to update them except as required by applicable
law.
WPD Pharmaceuticals (CSE:WBIO)
Historical Stock Chart
From Jul 2024 to Aug 2024
WPD Pharmaceuticals (CSE:WBIO)
Historical Stock Chart
From Aug 2023 to Aug 2024